Copyright © 2001 by the European Society of Cardiology.
Long-term clinical outcome after coronary balloon angioplasty. Identification of a population at low risk of recurrent events during 17 years of follow-up
The Department of Cardiac Catheterization and Interventional Cardiology, Thoraxcenter, Erasmus University and University Hospital Dijkzigt Rotterdam, The Netherlands
revised August 20, 2000; accepted August 23, 2000
Abstract
Aims This study reports the clinical outcome, up to 17 years, of the first 856 consecutive patients treated by coronary angioplasty at a single centre and attempts to identify a subgroup of patients at low risk of adverse events.
Methods and Results Follow-up status was established via hospital and general practitioner records and the civil registry. Median follow-up was 16 years. The overall 5-, 10-, 15- and 17-year survival was 90%, 78%, 64% and 58%, respectively and corresponding event-free survival was 53%, 33%, 22% and 19%. After 32% of patients had experienced a major adverse cardiac event in the first year, the annual coronary re-intervention incidence thereafter and, even beyond year 10, remained at 2%3%. Using multivariable Cox regression, significant independent predictors of mortality were advanced age, diabetes, multivessel disease and impaired left ventricular function at the time of PTCA. A subgroup of 26% of the patients with none of these risk factors had a survival rate similar to the general Dutch population matched for age and gender (at 5 years: 96%, at 10 years: 89% and at 15 years: 83%).
Conclusion Although the majority of patients (>80%) experienced a further cardiac event during the 17 years after their first angioplasty procedure, in those non-diabetics under 60 years with single-vessel disease and good left ventricular function, prognosis was similar to the general population.
Key Words: PTCA, follow-up, survival, risk stratification
f1 Correspondence: Ron T. van Domburg, University Hospital Rotterdam Dijkzigt, Thoraxcenter, Location 5 Midden, Room H 539, Dr. Molewaterplein 40, 3015 GD Rotterdam, The Netherlands.
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
K.-H. Mak and D. P. Faxon Clinical studies on coronary revascularization in patients with type 2 diabetes Eur. Heart J., June 2, 2003; 24(12): 1087 - 1103. [Abstract] [Full Text] [PDF] |
||||
![]() |
M Hamon, S Fradin, A Denizet, E Filippi-Codaccioni, G Grollier, and R Morello Prospective evaluation of the effect of an angiotensin I converting enzyme gene polymorphism on the long term risk of major adverse cardiac events after percutaneous coronary intervention Heart, March 1, 2003; 89(3): 321 - 325. [Abstract] [Full Text] [PDF] |
||||
![]() |
R.T van Domburg, D.P Foley, A Breeman, L.A van Herwerden, and P.W Serruys Coronary artery bypass graft surgery and percutaneous transluminal coronary angioplasty. Twenty-year clinical outcome Eur. Heart J., April 1, 2002; 23(7): 543 - 549. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Seabra-Gomes Every piece is important to build a puzzle. What can we learn from early experiences with balloon PTCA? Eur. Heart J., June 1, 2001; 22(11): 891 - 893. [PDF] |
||||

